Elotuzumab and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients: A Retrospective Study

ConclusionOur results suggest that some patients can benefit from Ed without an accompanying immunomodulatory agent and that efficacy can be achieved with the addition of lenalidomide at the time of progression. No new safety signals were detected, except for thrombocytopenia in 1 patient on Ed.This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fejh.13058

Source: European Journal of Haematology - March 10, 2018 Category: Hematology Authors: Zachary Gross, Ashkon Rahbari, Eric Wirtschafter, Tanya M. Spektor, Kyle A. Udd, Sean Bujarski, Michael Ghermezi, Jason D. Nosrati, Aleksandra Vidisheva, Benjamin Eades, Gary Cecchi, Tina Maluso, Regina Swift, James R. Berenson Tags: Case Report Source Type: research